-
公开(公告)号：US11930837B2
公开(公告)日：2024-03-19
申请号：US17403710
申请日：2021-08-16
Applicant: NOVARTIS AG
Inventor： Yaiza Diaz-De-Durana , Michael DiDonato , Christophe Filippi , Shelly Meeusen , Glen Spraggon
IPC: A61K38/20 , A23L7/10 , A23L7/104 , B02B1/04 , B02C4/06 , B02C4/16 , B02C9/00 , B02C23/18 , B02C23/40 , C07K16/46 , B02C15/14
CPC classification number: A23L7/197 , A23L7/104 , A61K38/2013 , B02B1/04 , B02C4/06 , B02C4/16 , B02C9/00 , B02C23/18 , B02C23/40 , C07K16/46 , A23V2002/00 , B02C15/14
Abstract: The present disclosure provides antibody cytokine engrafted proteins that bind to and stimulate intracellular signaling through a high affinity interleukin receptor. The antibody cytokine engrafted proteins find use in enhancing anti-inflammatory cell responses, and reducing pro-inflammatory effects in the treatment, amelioration and prevention of immune related disorders such as Type 1 Diabetes.
-
公开(公告)号：US12180291B2
公开(公告)日：2024-12-31
申请号：US18164519
申请日：2023-02-03
Applicant: Novartis AG
Inventor： Steven Bender , Tracy Charlton , Anna Galkin , Bernhard Hubert Geierstanger , Scott Martin Glaser , Shailaja Kasibhatla , Mark Knuth , Sabine Rottmann , Sarah Rue , Glen Spraggon , Tetsuo Uno
Abstract: This application discloses anti-CCR7 antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments. The invention also relates to methods of treating or preventing cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.
-
Patent Agency Ranking
公开(公告)号：US12006354B2
公开(公告)日：2024-06-11
申请号：US16616318
申请日：2018-05-22
Applicant: NOVARTIS AG
Inventor： Jonathan Deane , Yaiza Diaz-De-Durana , Michael DiDonato , Christophe Filippi , Glen Spraggon
IPC: C07K14/55 , A61K38/20 , A61K39/395 , A61K47/68 , A61P35/00 , C07K16/08 , C07K16/10 , C07K19/00 , C12N5/071 , C12N5/0783 , A61K39/00 , A61K45/06
CPC classification number: C07K16/1027 , A61K38/2013 , A61K39/3955 , A61K47/6801 , A61P35/00 , C07K14/55 , C07K19/00 , C12N5/0636 , C12N5/0682 , A61K2039/505 , A61K45/06 , C07K2317/56 , C07K2317/565 , C07K2317/94 , C07K2319/30
Abstract: The present disclosure provides for IL2 engrafted into the CDR sequences of an antibody having preferred therapeutic profiles over molecules known and used in the clinic. In particular, the provided antibody cytokine engrafted protein compositions increase or maintain CD8+ T effector cells while reducing the activity of Treg cells. Additionally, provided compositions convey improved half-life, stability and producibility over recombinant human IL2 formulations such as Proleukin®.
-
公开(公告)号：US20200270334A1
公开(公告)日：2020-08-27
申请号：US16616318
申请日：2018-05-22
Applicant: NOVARTIS AG
Inventor： Jonathan Deane , Yaiza Diaz-De-Durana , Michael DiDonato , Christophe Filippi , Glen Spraggon
IPC: C07K16/10 , C07K14/55 , C12N5/0783 , A61K39/395 , A61K45/06 , C12N5/071 , A61P35/00
Abstract: The present disclosure provides for IL2 engrafted into the CDR sequences of an antibody having preferred therapeutic profiles over molecules known and used in the clinic. In particular, the provided antibody cytokine engrafted protein compositions increase or maintain CD8+ T effector cells while reducing the activity of Treg cells. Additionally, provided compositions convey improved half-life, stability and produceability over recombinant human IL2 formulations such as Proleukin®.
-
公开(公告)号：US11634497B2
公开(公告)日：2023-04-25
申请号：US16482173
申请日：2018-02-01
Applicant: NOVARTIS AG
Inventor： Steven Bender , Tracy Charlton , Anna Galkin , Bernhard Hubert Geierstanger , Scott Martin Glaser , Shailaja Kasibhatla , Mark Knuth , Sabine Rottmann , Sarah Rue , Glen Spraggon , Tetsuo Uno
Abstract: This application discloses anti-CCR7 antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments. The invention also relates to methods of treating or preventing cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.
-
公开(公告)号：US20220346415A1
公开(公告)日：2022-11-03
申请号：US17813232
申请日：2022-07-18
Applicant: NOVARTIS AG
Inventor： Yaiza Diaz-De-Durana , Michael DiDonato , Christophe Filippi , Shelly Meeusen , Glen Spraggon
IPC: A23L7/10 , A23L7/104 , A61K38/20 , B02B1/04 , B02C4/06 , B02C4/16 , B02C9/00 , B02C23/18 , B02C23/40 , C07K16/46
Abstract: The present disclosure provides antibody cytokine engrafted proteins that bind to and stimulate intracellular signaling through a high affinity interleukin receptor. The antibody cytokine engrafted proteins find use in enhancing anti-inflammatory cell responses, and reducing pro-inflammatory effects in the treatment, amelioration and prevention of immune related disorders such as Type 1 Diabetes.
-
公开(公告)号：US11122825B2
公开(公告)日：2021-09-21
申请号：US16616138
申请日：2018-05-22
Applicant: NOVARTIS AG
Inventor： Yaiza Diaz-De-Durana , Michael DiDonato , Christophe Filippi , Shelly Meeusen , Glen Spraggon
IPC: A61K38/20 , A23L7/10 , A23L7/104 , B02C4/16 , B02C4/06 , B02C23/40 , B02B1/04 , B02C9/00 , B02C23/18 , C07K16/46 , B02C15/14
Abstract: The present disclosure provides antibody cytokine engrafted proteins that bind to and stimulate intracellular signaling through a high affinity interleukin receptor. The antibody cytokine engrafted proteins find use in enhancing anti-inflammatory cell responses, and reducing pro-inflammatory effects in the treatment, amelioration and prevention of immune related disorders such as Type 1 Diabetes.
-
-
-
-
-
-
Search Results
7
records
(took 0.012 seconds)
